View in EDS

Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.

Saved in:

Bibliographic Details
Title:	Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
Authors:	Douma LH; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands., van der Noort V; Department of Biometrics; Netherlands Cancer Institute, Amsterdam, Netherlands., Lalezari F; Department of Radiology; Netherlands Cancer Institute, Amsterdam, Netherlands., de Vries JF; Department of Biometrics; Netherlands Cancer Institute, Amsterdam, Netherlands., Monkhorst K; Department of Pathology; Netherlands Cancer Institute, Amsterdam, Netherlands., Smesseim I; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands., Baas P; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands., Schilder B; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands., Vermeulen M; Department of Biometrics; Netherlands Cancer Institute, Amsterdam, Netherlands., Burgers JA; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: s.burgers@nki.nl., de Gooijer CJ; Department of Thoracic Oncology; Netherlands Cancer Institute, Amsterdam, Netherlands.
Source:	The Lancet. Oncology [Lancet Oncol] 2025 Dec; Vol. 26 (12), pp. 1676-1684.
Publication Type:	Journal Article; Clinical Trial, Phase II
Journal Info:	Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1474-5488
DOI:	10.1016/S1470-2045(25)00514-5